Vascular Endothelial Growth Factor A VEGFA Inhibition: An Effective Treatment Strategy for Psoriasis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jan 11

PMID 38203230

Authors

Ya Chen

Zongguang Tai

Congcong Zhu

Qin Yu

Quangang Zhu

Zhongjian Chen

Affiliations

Soon will be listed here.

Abstract

Psoriasis is an inflammatory skin disease mediated by the immune system and characterized by an inflammatory ring, also known as an epithelial immune microenvironment (EIME). The interaction between the epithelial tissue of the skin and the immune system has a crucial role in the immune cycle of psoriasis. Although the formation of new blood vessels in skin lesions provides energy support for the proliferation of epidermal keratinocytes, the role of angiogenesis in psoriasis has not been extensively studied. Vascular endothelial growth factor A (VEGFA) is a key regulator of angiogenesis that has an important role in the development of psoriasis. VEGFA promotes angiogenesis and directly stimulates epidermal keratinocytes and infiltrating immune cells, thus contributing to the progression of psoriasis. Measuring VEGFA levels to identify angiogenic characteristics in psoriasis patients may be a predictive biomarker for disease severity and response to anti-angiogenic therapy. Clinical data have shown that anti-angiogenic therapy can improve skin lesions in psoriasis patients. Therefore, this study aimed to uncover the underestimated role of blood vessels in psoriasis, explore the relationship between VEGFA and keratinocytes in the EIME, and inspire innovative drug therapies for the treatment of psoriasis.

Citing Articles

Vascular Endothelial Growth Factor a Promotes Chronic Itch via VEGFA-VEGFR2-PI3K-TRPV1 Axis in Allergic Contact Dermatitis.

Liu Q, Liu H, Ye L, Li T, Chen Z, Wang Y J Inflamm Res. 2024; 17:7423-7439.

PMID: 39435259 PMC: 11492922. DOI: 10.2147/JIR.S470094.

References

de Rie M, Goedkoop A, Bos J . Overview of psoriasis. Dermatol Ther. 2004; 17(5):341-9. DOI: 10.1111/j.1396-0296.2004.04037.x. View

Lechertier T, Reynolds L, Kim H, Pedrosa A, Gomez-Escudero J, Munoz-Felix J . Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth. Nat Commun. 2020; 11(1):2810. PMC: 7272651. DOI: 10.1038/s41467-020-16618-6. View

Vasudev N, Reynolds A . Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014; 17(3):471-94. PMC: 4061466. DOI: 10.1007/s10456-014-9420-y. View

Wallace L, Roberts-Thompson L, Reichelt J . Deletion of K1/K10 does not impair epidermal stratification but affects desmosomal structure and nuclear integrity. J Cell Sci. 2012; 125(Pt 7):1750-8. DOI: 10.1242/jcs.097139. View

Lopes-Coelho F, Martins F, Pereira S, Serpa J . Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int J Mol Sci. 2021; 22(7). PMC: 8038573. DOI: 10.3390/ijms22073765. View

Henno A, Blacher S, Lambert C, Colige A, Seidel L, Noel A . Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis. Br J Dermatol. 2008; 160(3):581-90. DOI: 10.1111/j.1365-2133.2008.08889.x. View

Bhushan M, McLaughlin B, Weiss J, Griffiths C . Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999; 141(6):1054-60. DOI: 10.1046/j.1365-2133.1999.03205.x. View

Cheng S, Zhang X, Feng Q, Chen J, Shen L, Yu P . Astragaloside IV exerts angiogenesis and cardioprotection after myocardial infarction via regulating PTEN/PI3K/Akt signaling pathway. Life Sci. 2019; 227:82-93. DOI: 10.1016/j.lfs.2019.04.040. View

Li M, Kroetz D . Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmacol Ther. 2017; 182:152-160. PMC: 5785435. DOI: 10.1016/j.pharmthera.2017.08.012. View

10.

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

11.

Griffioen A, Dudley A . Angiogenesis: a year in review. Angiogenesis. 2021; 24(2):195-196. PMC: 8164393. DOI: 10.1007/s10456-021-09798-2. View

12.

Xu M, Deng J, Xu K, Zhu T, Han L, Yan Y . In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. Theranostics. 2019; 9(9):2475-2488. PMC: 6526001. DOI: 10.7150/thno.31144. View

13.

Zhang J, Ma W . Nerve growth factor regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes via PI3K/mTOR pathway. Genet Mol Res. 2014; 13(4):9324-35. DOI: 10.4238/2014.January.24.14. View

14.

White A, Bix G . VEGFA Isoforms as Pro-Angiogenic Therapeutics for Cerebrovascular Diseases. Biomolecules. 2023; 13(4). PMC: 10136305. DOI: 10.3390/biom13040702. View

15.

Hanssen S, van der Vleuten C, van Erp P, Seyger M, van de Kerkhof P . The effect of adalimumab on the vasculature in psoriatic skin lesions. J Dermatolog Treat. 2018; 30(3):221-226. DOI: 10.1080/09546634.2018.1506082. View

16.

Qi M, Huang X, Zhou L, Zhang J . Four polymorphisms of VEGF (+405C>G, -460T>C, -2578C>A, and -1154G>A) in susceptibility to psoriasis: a meta-analysis. DNA Cell Biol. 2014; 33(4):234-44. PMC: 3967360. DOI: 10.1089/dna.2013.2252. View

17.

Ferrari D, Casciano F, Secchiero P, Reali E . Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis. Int J Mol Sci. 2021; 22(17). PMC: 8430580. DOI: 10.3390/ijms22179449. View

18.

Connolly D, Heuvelman D, Nelson R, Olander J, Eppley B, Delfino J . Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest. 1989; 84(5):1470-8. PMC: 304011. DOI: 10.1172/JCI114322. View

19.

Zhou J, Gao Y, Yi X, Ding Y . Ginsenoside Rh2 Suppresses Neovascularization in Xenograft Psoriasis Model. Cell Physiol Biochem. 2015; 36(3):980-7. DOI: 10.1159/000430272. View

20.

Paramio J, Casanova M, Segrelles C, Mittnacht S, Lane E, Jorcano J . Modulation of cell proliferation by cytokeratins K10 and K16. Mol Cell Biol. 1999; 19(4):3086-94. PMC: 84102. DOI: 10.1128/MCB.19.4.3086. View